Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

The Diabetes Transition of Hospital Care (DiaTOHC) Pilot Study: A Randomized Controlled Trial of an Intervention Designed to Reduce Readmission Risk of Adults with Diabetes

Version 1 : Received: 4 January 2022 / Approved: 6 January 2022 / Online: 6 January 2022 (11:40:43 CET)

How to cite: Rubin, D.J.; Gogineni, P.; Deak, A.; Vaz, C.L.; Watts, S.; Recco, D.; Dillard, F.R.; Wu, J.; Karunakaran, A.; Kondamuri, N.; Zhao, H.; Naylor, M.D.; Golden, S.H.; Allen, S. The Diabetes Transition of Hospital Care (DiaTOHC) Pilot Study: A Randomized Controlled Trial of an Intervention Designed to Reduce Readmission Risk of Adults with Diabetes. Preprints 2022, 2022010078 (doi: 10.20944/preprints202201.0078.v1). Rubin, D.J.; Gogineni, P.; Deak, A.; Vaz, C.L.; Watts, S.; Recco, D.; Dillard, F.R.; Wu, J.; Karunakaran, A.; Kondamuri, N.; Zhao, H.; Naylor, M.D.; Golden, S.H.; Allen, S. The Diabetes Transition of Hospital Care (DiaTOHC) Pilot Study: A Randomized Controlled Trial of an Intervention Designed to Reduce Readmission Risk of Adults with Diabetes. Preprints 2022, 2022010078 (doi: 10.20944/preprints202201.0078.v1).

Abstract

Hospital readmission within 30 days of discharge (30-day readmission) is a high-priority quality measure and cost target. The purpose of this study was to explore the feasibility and efficacy of the Diabetes Transition of Hospital Care (DiaTOHC) Program on readmission risk in high-risk adults with diabetes. This was a non-blinded pilot randomized controlled trial (RCT) that compared usual care (UC) to DiaTOHC at a safety-net hospital. The primary outcome was all-cause 30-day readmission. Between 10/16/2017 and 05/30/2019, 115 patients were randomized. In the intention-to-treat (ITT) population, 14 (31.1%) of 45 DiaTOHC subjects and 15 (32.6%) of 46 UC subjects had a 30-day readmission (p=0.88) while 35.6% DiaTOHC and 39.1% UC subjects had a 30-day readmission or ED visit (p=0.72). The Intervention:UC cost ratio was 0.33 (0.13-0.79)95%CI (p<0.01). Among the 69 subjects with baseline HbA1c >7.0% (53 mmol/mol), 30-day readmission rates were 23.5% (DiaTOHC) and 31.4% (UC, p=0.46) and composite 30-day readmission or ED visit rates were 26.5% (DiaTOHC) and 40.0% (UC, p=0.23). In this subgroup, the Intervention:UC cost ratio was 0.21 (0.08-0.58)95%CI (p=0.002). The DiaTOHC Program is feasible and may decrease combined 30-day readmission/ED visit risk as well as healthcare costs among patients with higher HbA1c levels.

Keywords

rehospitalization; transition care; pilot study; prospective randomized trial

Subject

MEDICINE & PHARMACOLOGY, General Medical Research

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.